Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 35.44
ZGNX's Cash to Debt is ranked higher than
79% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. ZGNX: 35.44 )
ZGNX' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 35.44

Equity to Asset 0.51
ZGNX's Equity to Asset is ranked higher than
59% of the 728 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. ZGNX: 0.51 )
ZGNX' s 10-Year Equity to Asset Range
Min: -3.87   Max: 0.51
Current: 0.51

-3.87
0.51
F-Score: 4
Z-Score: -1.57
M-Score: -0.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -161.13
ZGNX's Operating margin (%) is ranked lower than
53% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. ZGNX: -161.13 )
ZGNX' s 10-Year Operating margin (%) Range
Min: -299.29   Max: -107
Current: -161.13

-299.29
-107
Net-margin (%) -244.93
ZGNX's Net-margin (%) is ranked lower than
54% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. ZGNX: -244.93 )
ZGNX' s 10-Year Net-margin (%) Range
Min: -313.81   Max: -106.9
Current: -244.93

-313.81
-106.9
ROE (%) -438.81
ZGNX's ROE (%) is ranked lower than
58% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. ZGNX: -438.81 )
ZGNX' s 10-Year ROE (%) Range
Min: -901.02   Max: -256.02
Current: -438.81

-901.02
-256.02
ROA (%) -71.87
ZGNX's ROA (%) is ranked lower than
55% of the 777 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. ZGNX: -71.87 )
ZGNX' s 10-Year ROA (%) Range
Min: -164.96   Max: -58.73
Current: -71.87

-164.96
-58.73
ROC (Joel Greenblatt) (%) -408.82
ZGNX's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.60 vs. ZGNX: -408.82 )
ZGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -523.81   Max: -212.31
Current: -408.82

-523.81
-212.31
Revenue Growth (%) -62.30
ZGNX's Revenue Growth (%) is ranked lower than
55% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. ZGNX: -62.30 )
ZGNX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -62.3
Current: -62.3

EBITDA Growth (%) -64.40
ZGNX's EBITDA Growth (%) is ranked lower than
54% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. ZGNX: -64.40 )
ZGNX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -64.4
Current: -64.4

EPS Growth (%) -65.20
ZGNX's EPS Growth (%) is ranked lower than
52% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ZGNX: -65.20 )
ZGNX' s 10-Year EPS Growth (%) Range
Min: 0   Max: -65.2
Current: -65.2

» ZGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ZGNX Guru Trades in Q3 2013

Chuck Royce 1,466,078 sh (unchged)
» More
Q4 2013

ZGNX Guru Trades in Q4 2013

Paul Tudor Jones 41,754 sh (New)
Steven Cohen 21,792 sh (New)
Chuck Royce 1,266,078 sh (-13.64%)
» More
Q1 2014

ZGNX Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Chuck Royce 734,478 sh (-41.99%)
» More
Q2 2014

ZGNX Guru Trades in Q2 2014

Chuck Royce 734,478 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ZGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.76
ZGNX's P/B is ranked higher than
71% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. ZGNX: 2.76 )
ZGNX' s 10-Year P/B Range
Min: 2.45   Max: 202
Current: 2.76

2.45
202
P/S 5.00
ZGNX's P/S is ranked higher than
54% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. ZGNX: 5.00 )
ZGNX' s 10-Year P/S Range
Min: 0.33   Max: 15.16
Current: 5

0.33
15.16
EV-to-EBIT 77.39
ZGNX's EV-to-EBIT is ranked higher than
66% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. ZGNX: 77.39 )
ZGNX' s 10-Year EV-to-EBIT Range
Min: 41.4   Max: 113.5
Current: 77.39

41.4
113.5
Current Ratio 2.13
ZGNX's Current Ratio is ranked higher than
65% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. ZGNX: 2.13 )
ZGNX' s 10-Year Current Ratio Range
Min: 0.85   Max: 3.24
Current: 2.13

0.85
3.24
Quick Ratio 1.84
ZGNX's Quick Ratio is ranked higher than
70% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. ZGNX: 1.84 )
ZGNX' s 10-Year Quick Ratio Range
Min: 0.32   Max: 2.54
Current: 1.84

0.32
2.54

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.25
ZGNX's Price/Net Cash is ranked higher than
92% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ZGNX: 11.25 )
ZGNX' s 10-Year Price/Net Cash Range
Min: 16.83   Max: 16.83
Current: 11.25

Price/Net Current Asset Value 6.75
ZGNX's Price/Net Current Asset Value is ranked higher than
94% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ZGNX: 6.75 )
ZGNX' s 10-Year Price/Net Current Asset Value Range
Min: 10.1   Max: 10.1
Current: 6.75

Price/Tangible Book 2.75
ZGNX's Price/Tangible Book is ranked higher than
80% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.53 vs. ZGNX: 2.75 )
ZGNX' s 10-Year Price/Tangible Book Range
Min: 3.89   Max: 142.25
Current: 2.75

3.89
142.25
Price/Median PS Value 1.71
ZGNX's Price/Median PS Value is ranked higher than
59% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. ZGNX: 1.71 )
ZGNX' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 3.78
Current: 1.71

0.17
3.78
Earnings Yield (Greenblatt) 1.30
ZGNX's Earnings Yield (Greenblatt) is ranked lower than
51% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. ZGNX: 1.30 )
ZGNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 2.4
Current: 1.3

0.9
2.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:Z08.Germany
Zogenix, Inc. is a Delaware Corporation. It is a pharmaceutical company, engaged in the commercializing and developing products for the treatment of central nervous system disorders and pain. The Company's first commercial product, Sumavel DosePro (sumatriptan injection) Needle-free Delivery System, was launched in January 2010. Sumavel DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Sumavel DosePro is the first drug product approved by the U.S. Food and Drug Administration, or FDA that allows for the needle-free, subcutaneous delivery of medication. Sumavel DosePro may offer a faster-acting and more efficacious treatment alternative to oral and nasal triptans and simple, convenient administration when compared to traditional, needle-based sumatriptan injection. The Company's strategy is to commercialize and develop differentiated central nervous system and pain therapeutics that can address significant unmet medical needs and overcome limitations of existing products. The Company's main product candidate, Zohydro, is a novel, oral, single-entity controlled-release formulation of hydrocodone currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. The Company also develops Relday, a proprietary, long-acting injectable formulation of risperidone using Durect Corporation's SABER controlled-release formulation technology in combination with DosePro needle-free, subcutaneous drug delivery system through a 2011 development and license agreement with Durect Corporation.
» More Articles for ZGNX

Headlines

Articles On GuruFocus.com
comment on ZGNX Mar 23 2013 
Weekly CFO Buys Highlight: NGL, UNTK, ZGNX, VTSS, RVSB Dec 24 2012 
(ZGNX) CEO Roger Hawley buys 10,000 Shares Dec 06 2010 

More From Other Websites
ZOGENIX, INC. Financials Aug 19 2014
ZOGENIX, INC. Files SEC form 8-K, Other Events Aug 14 2014
Does Zogenix Need a Painkiller? A Drug Maker Struggles With Controversy Aug 07 2014
ZOGENIX, INC. Files SEC form 10-Q, Quarterly Report Aug 06 2014
Zogenix Inc Earnings Call scheduled for 4:30 pm ET today Aug 05 2014
ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 05 2014
Zogenix Reports Second Quarter 2014 Financial Results Aug 05 2014
Q2 2014 Zogenix, Inc. Earnings Release - After Market Close Aug 05 2014
Express Scripts drops Amgen anemia drugs from formulary Aug 01 2014
Zogenix Announces Departure of Chief Commercial Officer, Scott Shively Aug 01 2014
ZOGENIX, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jul 24 2014
Zogenix Announces Conference Call and Webcast to Present Second Quarter 2014 Financial Results Jul 22 2014
Despite The Sell-Off, Zohydro Is A Falling Knife Too Dangerous To Catch Jul 22 2014
Zogenix Announces Appointment of David Brushwood, J.D., R.Ph., to External Safe Use Board Jul 17 2014
Zogenix announces patent for DosePro Needle-free Delivery System Jul 14 2014
Zogenix Announces New Patent Valid Through 2032 For DosePro(R) Needle-Free Delivery System Jul 14 2014
ZOGENIX, INC. Files SEC form 8-K, Other Events Jul 09 2014
Zogenix Reports Positive Development on U.S. District Court Ruling Jul 09 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK